News

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center detailed some of consequences of undiagnosed or misdiagnosed LGS, and how it may impact long-term care for eligible patients. [WATCH TIME: 4 minutes]

Using more than 4 million eligible pregnancies, results suggest no substantially increased risk of autism spectrum disorder after prenatal exposure to either topiramate or lamotrigine.

Cure SMA introduces tools aiding in SMA clinical trial navigation and participation empowerment.

Lindsey Lee Lair, MD, a neurologist and vice president of clinical development at Biohaven Pharmaceuticals, provided insight on an ongoing pivotal trial assessing the impacts of taldefgrobep alfa, a myostatin inhibitor, in patients with SMA.

In patients with relapsing-remitting MS who achieved NEDA under highly effective DMT, sNfL concentrations were low and stable, suggesting a potential role for sNfL for long-term monitoring of inflammatory disease activity.

The director of Dysautonomia Clinic talked about advocating for recognition and research into neurological symptoms that have long been overlooked in patients with Long COVID. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Alkermes embarks on the phase 2 Vibrance-1 trial to evaluate the safety and efficacy of ALKS 2680 against placebo as a once-daily treatment for narcolepsy type 1.

Bezisterim-treated patients showed age deceleration across various DNA methylation clocks, indicating potential anti-aging effects.

In a recent study assessing basal ganglia activity during REM sleep, results revealed that elevated beta power may be correlated with the severity of REM sleep behavior disorder in Parkinson disease.

A recent study recognized anti-DAGLA autoantibodies in the cerebrospinal fluid of a small group of patients, suggesting that it could be a potential biomarker for diagnosing cerebellar ataxia.

Neurology News Network. for the week ending May 11, 2024. [WATCH TIME: 4 minutes]

Avidity Biosciences is anticipated to initiate its phase 3 HARBOR trial assessing AOC 1001 as a treatment for patients with myotonic dystrophy type 1 in the second quarter of 2024.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 10, 2024.

Depression prior to PD diagnosis predicts increased dementia risk and mortality, emphasizing its significance in disease progression.

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester discussed treatment response and safety findings from the phase 3 ACCORD study assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 6 minutes]

ABP-450, a botulinum toxin type A complex agent, failed to meet either primary or secondary end points in a cohort of 325 patients with chronic migraine.

Catch up on any of the neurology news headlines you may have missed over the course of April 2024, compiled all into one place by the NeurologyLive® team.

Jacqueline A. French, MD, professor of neurology at NYU Grossman School of Medicine, provided comments on a recently published study explaining the issues with diagnosing epilepsy in emergency department settings.

Clinical trials assessing cell therapies for Parkinson disease treatment may show early potential in improving both motor and nonmotor symptoms.

Kremens gave closing thoughts on the promise of the Parkinson disease research field, the outlook of drug development, and what clinicians should be excited for next.

Treatment with SAGE-324/BIIB124 for essential tremor resulted in adverse events that included somnolence, dizziness, fatigue, and balance disorder.

Daniel Kremens, MD, JD, described positive 18-month data on bemdaneprocel, an investigational cell-based approach for patients with Parkinson disease.

Findings from a recent study suggest that the presence of negative myoclonus may serve as a diagnostic clue for progressive myoclonus ataxia, suggesting the presence of genetic disorders.

Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.

The neurologist at Mass General Hospital discussed adopting AI technologies in neurology practice, emphasizing the importance of addressing equity concerns alongside technological advancements. [WATCH TIME: 5 minutes]

Subgroup analyses support PrimeC’s potential in ALS treatment, aiming to inform upcoming trials for efficacy.

As the company gains more information about the patient death, dosing in the other phase 3 trial, CIFFREO, has been paused until further notice.